Novo Nordisk's Pill War: A Courtroom Win, a Prescription Lead, and a Stock That Won't Cooperate
Published on 08/17/2026 at 12:41 | Redaktion boerse-global.de
The Danish pharmaceutical giant finds itself in an unusual position: winning battles while losing the war of investor sentiment. A Dutch court ruling in its favor on intellectual property, combined with a growing lead in the oral weight-loss pill market, has done little to arrest a slide that has erased more than a quarter of the company's market value since January.
A Legal Shield That Holds
The Hague District Court handed Novo Nordisk a decisive victory on August 5, issuing a preliminary injunction against Ceban Ziekenhuisfarmacie over its compounded semaglutide nasal spray. The court found the Dutch company in violation of Novo Nordisk's supplementary protection certificate, ruling that the product infringed on the extended patent protection for semaglutide.
The underlying European patent (EP 1 863 839) expired in March, but the supplementary protection certificate extends exclusivity in the Netherlands until March 19, 2031. Ceban must now halt sales immediately, remove product listings, disclose supply chain information, and cover Novo Nordisk's legal costs.
The ruling underscores how aggressively the company defends its intellectual property around semaglutide, even as cheaper compounding pharmacies and copycat manufacturers circle the lucrative GLP-1 market. For shareholders, it offers a measure of reassurance that European patent barriers remain intact — no small consideration given the intensifying competitive landscape around Wegovy and the oral semaglutide pill.
The Pill Race: Time Advantage vs. Efficacy Claims
The courtroom success arrives amid a fierce contest for the oral weight-loss market, where Danske Bank sees Novo Nordisk holding a surprising edge over Eli Lilly. The Danish bank believes the homegrown champion can win the US market for anti-obesity pills, even though most analysts currently favor Lilly.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Lilly launched its oral candidate Foundayo on Monday, and Citi analyst Geoff Meacham argues that the drug's simpler administration more than compensates for a 2.2 percentage point disadvantage in weight loss compared with Novo Nordisk's offering. But Novo Nordisk counters with a roughly three-month head start in the market and a few percentage points more in weight reduction. The Wegovy pill has already surpassed five million prescriptions.
The rivalry has turned litigious. Novo Nordisk has sued Lilly over misleading advertising, centering on how each company presents efficacy data. Lilly's Zepbound achieves 20.2 percent weight loss after 72 weeks, while the older Wegovy dosage delivers 13.7 percent. The newer 7.2-mg version of Wegovy reaches 19 percent — and the FDA has now approved this higher dose, which showed 20.7 percent weight loss after 72 weeks versus 15 percent at standard dosing, with Type-2 diabetics seeing 14.1 percent. A priority review voucher accelerated the approval.
Demand Beyond the US
The European Commission approved the Wegovy pill in July, and interest is building in the United Arab Emirates, where the tablet form is drawing first-time users at prices between 779 and 1,610 dirham depending on dosage. Pharmacists there are reportedly advising early orders amid concerns about supply constraints.
Novo CEO Mike Doustdar frames the opportunity in broader terms: more than 100 million Americans suffer from obesity, yet only a fraction currently have access to GLP-1 medications. Wider adoption, he argues, could reduce healthcare costs and boost economic productivity.
A Crowded Field Beyond Lilly
The competitive threat extends well beyond the two market leaders. Amgen has halted its Phase 1 candidate AMG 513 to focus on MariTide, now in Phase 3. Pfizer targets a 2028 launch for its monthly injectable verobenatide, while Structure Therapeutics' oral candidate aleniglipron posted weight loss of up to 16.3 percent in a 44-week study. The pivotal Phase 3 data from these challengers, expected in 2027 and 2028, will likely shape the market's medium-term outlook.
The Stock Tells a Different Story
None of this has lifted the share price. The stock closed Friday at 39.40 euros, down 2.6 percent on the day, and has shed 10 percent over the past month. Year-to-date losses stand at 11 percent, with the shares trading 28 percent below the January 52-week high of 54.86 euros.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Several headwinds explain the disconnect. Late July brought disappointment from the ZEUS trial of Ziltivekimab: while the drug hit its mark on inflammatory markers, it failed to significantly reduce major cardiovascular events versus placebo — a shadow that continues to hang over the stock. Even an expanded share buyback program has failed to stem the decline. Through August 7, the company had repurchased nearly 27.9 million B-shares at an average price of 279.01 Danish kroner, with an additional program of up to 11.2 billion kroner running through February 2027.
Monday brings a technical drag of its own: the stock trades ex-dividend on a payout of 0.579 US dollars. The RSI sits near 40, suggesting the stock is not yet oversold, while a 5 percent gap below the 50-day moving average confirms the short-term downtrend.
Investors now look to the Capital Markets Day on September 21, where management is expected to outline its strategic direction for the coming years. Until then, the legal victory and the oral pill lead remain bright spots in an otherwise clouded picture — positive signals that have yet to move the needle where it matters most.
Ad
Novo Nordisk Stock: New Analysis - 17 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
